New Alzheimer’s Research links Inflammation and Amyloid Beta, Offering New Treatment Pathways
alzheimer’s disease, a devastating neurodegenerative condition, progressively erodes brain cells and their connections, ultimately leading to memory loss and cognitive decline. While the hallmark of the disease has long been understood as the destruction of these vital neural networks, the precise mechanisms initiating this destruction have remained elusive. Traditionally, research has focused on amyloid beta, a protein fragment that accumulates in the brain, but emerging evidence points to a complex interplay of factors including tau proteins, inflammation, and immune responses.
Recent research published in the Proceedings of the National Academy of Sciences suggests a crucial connection between two leading theories of Alzheimer’s growth: amyloid beta accumulation and chronic inflammation. Scientists at stanford University, lead by Carla Shatz, have discovered that these seemingly distinct processes may converge on a shared molecular pathway, offering a new perspective on the disease’s origins and potential therapeutic targets.
The Role of Synaptic Pruning and the LilrB2 Receptor
The study centers around a receptor called LilrB2, previously identified by Shatz’s team as a key player in synaptic pruning – a natural process of eliminating unnecessary connections between neurons during brain development and learning. Prior research demonstrated that amyloid beta can bind to LilrB2, triggering neurons to remove synapses, and that genetically removing the receptor protected mice from memory loss in Alzheimer’s models.
This new research expands on these findings by investigating the role of the complement cascade, a part of the immune system responsible for eliminating pathogens and damaged cells.Chronic inflammation, a known risk factor for Alzheimer’s, activates the complement cascade. Researchers hypothesized that molecules released during inflammation might interact with LilrB2 in a similar way to amyloid beta.
Inflammation Directly Impacts Synapse Loss
Through rigorous testing, the team identified a protein fragment, C4d, released during the complement cascade, that binds strongly to the LilrB2 receptor. Remarkably, injecting C4d directly into the brains of healthy mice resulted in the stripping away of synapses, demonstrating a direct link between inflammation and synapse loss.
“Lo and behold, it stripped synapses off neurons,” Shatz explained, highlighting the surprising discovery that C4d, previously thought to be inactive, actively contributes to synapse elimination.
Rethinking alzheimer’s Pathology and Treatment Strategies
these findings suggest that both amyloid beta and inflammation may drive synapse loss through the same biological mechanism, challenging the conventional view of Alzheimer’s as solely a disease of amyloid plaque buildup. The research also suggests that neurons are not merely passive victims of the disease, but actively participate in synapse removal.
This new understanding has notable implications for Alzheimer’s treatment. Current FDA-approved therapies primarily focus on breaking down amyloid plaques, with limited success and potential side effects like headaches and brain bleeding. Shatz argues that targeting receptors like LilrB2, which directly control synapse removal, could offer a more effective approach.
“Busting up amyloid plaques hasn’t worked that well…and even if they worked well, you’re only going to solve part of the problem,” Shatz stated. “Protecting synapses may be possible to preserve memory itself.”
The study, conducted by researchers from Stanford University and the California Institute of Technology, received funding from the National Institutes of Health, the Sapp Family Foundation, and the Knight Initiative for Brain Resilience. Human brain tissue samples were provided by the Neurodegenerative Disease Brain Bank at the University of California, San Francisco.
Related reading